{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:45:21Z","timestamp":1784205921146,"version":"3.55.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"DOI":"10.1038\/s41587-026-03115-2","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:05:04Z","timestamp":1778663104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5614-2313","authenticated-orcid":false,"given":"A.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-5129","authenticated-orcid":false,"given":"T.","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6007-1988","authenticated-orcid":false,"given":"Q. T. C.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-5534","authenticated-orcid":false,"given":"A.","family":"Rudra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Trongjit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. S.","family":"Vanrobaeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4255-0492","authenticated-orcid":false,"given":"R.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-4143","authenticated-orcid":false,"given":"R.","family":"Weissleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Garris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-4798","authenticated-orcid":false,"given":"D. G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"3115_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298\u2013312 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"3115_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer\u2013immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"3115_CR3","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825\u20131863 (2024).","journal-title":"Cancer Cell"},{"key":"3115_CR4","doi-asserted-by":"publisher","first-page":"e009063","DOI":"10.1136\/jitc-2024-009063","volume":"12","author":"LA Emens","year":"2024","unstructured":"Emens, L. A. et al. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J. Immunother. Cancer 12, e009063 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"3115_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17\u201335 (2020).","journal-title":"Immunity"},{"key":"3115_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"3115_CR7","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"3115_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526\u2013543 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"3115_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3115_CR10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41573-024-01041-z","volume":"23","author":"A Gupta","year":"2024","unstructured":"Gupta, A., Rudra, A., Reed, K., Langer, R. & Anderson, D. G. Advanced technologies for the development of infectious disease vaccines. Nat. Rev. Drug Discov. 23, 914\u2013938 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3115_CR11","doi-asserted-by":"publisher","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","volume":"11","author":"SL Hewitt","year":"2019","unstructured":"Hewitt, S. L. et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs. Sci. Transl. Med. 11, eaat9143 (2019).","journal-title":"Sci. Transl. Med."},{"key":"3115_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s43018-020-0095-6","volume":"1","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nat. Cancer 1, 882\u2013893 (2020).","journal-title":"Nat. Cancer"},{"key":"3115_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm8451","volume":"16","author":"B Brook","year":"2025","unstructured":"Brook, B. et al. Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70. Sci. Transl. Med. 16, eadm8451 (2025).","journal-title":"Sci. Transl. Med."},{"key":"3115_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-022-00557-6","volume":"22","author":"RA Saxton","year":"2023","unstructured":"Saxton, R. A., Glassman, C. R. & Garcia, K. C. Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov. 22, 21\u201337 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3115_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","volume":"25","author":"DB Stetson","year":"2006","unstructured":"Stetson, D. B. & Medzhitov, R. Type I interferons in host defense. Immunity 25, 373\u2013381 (2006).","journal-title":"Immunity"},{"key":"3115_CR16","first-page":"2950","volume":"9","author":"CM van Herpen","year":"2003","unstructured":"van Herpen, C. M. et al. Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clin. Cancer Res. 9, 2950\u20132956 (2003).","journal-title":"Clin. Cancer Res."},{"key":"3115_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cncr.10631","volume":"95","author":"O Eton","year":"2002","unstructured":"Eton, O. et al. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 95, 127\u2013134 (2002).","journal-title":"Cancer"},{"key":"3115_CR18","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-\u03b3 production. Blood 90, 2541\u20132548 (1997).","journal-title":"Blood"},{"key":"3115_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer\u2013immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"3115_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"S-C Sun","year":"2017","unstructured":"Sun, S.-C. The non-canonical NF-\u03baB pathway in immunity and inflammation. Nat. Rev. Immunol. 17, 545\u2013558 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"3115_CR21","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity 49, 1148\u20131161 (2018).","journal-title":"Immunity"},{"key":"3115_CR22","doi-asserted-by":"publisher","first-page":"14664","DOI":"10.1073\/pnas.1520627112","volume":"112","author":"AK Katakam","year":"2015","unstructured":"Katakam, A. K. et al. Dendritic cells require NIK for CD40-dependent cross-priming of CD8+ T cells. Proc. Natl Acad. Sci. USA 112, 14664\u201314669 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3115_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41590-019-0450-x","volume":"20","author":"V Durai","year":"2019","unstructured":"Durai, V. et al. Cryptic activation of an Irf8 enhancer governs cDC1 fate specification. Nat. Immunol. 20, 1161\u20131173 (2019).","journal-title":"Nat. Immunol."},{"key":"3115_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/ni.3197","volume":"16","author":"GE Grajales-Reyes","year":"2015","unstructured":"Grajales-Reyes, G. E. et al. Batf3 maintains autoactivation of Irf8 for commitment of a CD8\u03b1+ conventional DC clonogenic progenitor. Nat. Immunol. 16, 708\u2013717 (2015).","journal-title":"Nat. Immunol."},{"key":"3115_CR25","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.immuni.2022.06.006","volume":"55","author":"T Lan\u00e7a","year":"2022","unstructured":"Lan\u00e7a, T. et al. IRF8 deficiency induces the transcriptional, functional, and epigenetic reprogramming of cDC1 into the cDC2 lineage. Immunity 55, 1431\u20131447 (2022).","journal-title":"Immunity"},{"key":"3115_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41577-020-00413-x","volume":"21","author":"DA Anderson","year":"2021","unstructured":"Anderson, D. A., Dutertre, C.-A., Ginhoux, F. & Murphy, K. M. Genetic models of human and mouse dendritic cell development and function. Nat. Rev. Immunol. 21, 101\u2013115 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"3115_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell. Mol. Immunol. 20, 432\u2013447 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"3115_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cell.2007.10.030","volume":"131","author":"E Varfolomeev","year":"2007","unstructured":"Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-\u03baB activation, and TNF\u03b1-dependent apoptosis. Cell 131, 669\u2013681 (2007).","journal-title":"Cell"},{"key":"3115_CR29","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1038\/oncsis.2016.26","volume":"5","author":"AC West","year":"2016","unstructured":"West, A. C. et al. The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. Oncogenesis 5, e216 (2016).","journal-title":"Oncogenesis"},{"key":"3115_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn9083","volume":"386","author":"E Ascic","year":"2025","unstructured":"Ascic, E. et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2025).","journal-title":"Science"},{"key":"3115_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4817","volume":"8","author":"O Zimmermannova","year":"2025","unstructured":"Zimmermannova, O. et al. Restoring tumor immunogenicity with dendritic cell reprogramming. Sci. Immunol. 8, eadd4817 (2025).","journal-title":"Sci. Immunol."},{"key":"3115_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff, E. R. S. et al. High cost of chimeric antigen receptor T-cells: challenges and solutions. Am. Soc. Clin. Oncol. Educ. Book 43, e397912 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3115_CR33","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1038\/s41591-024-03231-z","volume":"30","author":"B Dropuli\u0107","year":"2024","unstructured":"Dropuli\u0107, B. CAR-T and cellular gene therapies are too expensive. Nat. Med. 30, 2714 (2024).","journal-title":"Nat. Med."},{"key":"3115_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285\u2013298 (2018).","journal-title":"Hum. Gene Ther."},{"key":"3115_CR35","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"L Angela","year":"2023","unstructured":"Angela, L. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 389, 1203\u20131210 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3115_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202400633","volume":"9","author":"R Das","year":"2025","unstructured":"Das, R. et al. Lipid nanoparticle\u2013mRNA engineered dendritic cell based adoptive cell therapy enhances cancer immune response. Small Methods 9, 2400633 (2025).","journal-title":"Small Methods"},{"key":"3115_CR37","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.4049\/jimmunol.177.3.1618","volume":"177","author":"RL Reinhardt","year":"2006","unstructured":"Reinhardt, R. L., Hong, S., Kang, S.-J., Wang, Z. & Locksley, R. M. Visualization of IL-12\/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation. J. Immunol. 177, 1618\u20131627 (2006).","journal-title":"J. Immunol."},{"key":"3115_CR38","doi-asserted-by":"publisher","first-page":"e33419","DOI":"10.1371\/journal.pone.0033419","volume":"7","author":"ME Belderbos","year":"2012","unstructured":"Belderbos, M. E. et al. Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factors. PLoS ONE 7, e33419 (2012).","journal-title":"PLoS ONE"},{"key":"3115_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1471-4906(03)00067-X","volume":"24","author":"F Brombacher","year":"2003","unstructured":"Brombacher, F., Kastelein, R. A. & Alber, G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 24, 207\u2013212 (2003).","journal-title":"Trends Immunol."},{"key":"3115_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2011-06-363564","volume":"119","author":"F Spadaro","year":"2012","unstructured":"Spadaro, F. et al. IFN-\u03b1 enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119, 1407\u20131417 (2012).","journal-title":"Blood"},{"key":"3115_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev-immunol-032713-120204","volume":"34","author":"TL Murphy","year":"2016","unstructured":"Murphy, T. L. et al. Transcriptional control of dendritic cell development. Annu. Rev. Immunol. 34, 93\u2013119 (2016).","journal-title":"Annu. Rev. Immunol."},{"key":"3115_CR42","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nature11531","volume":"490","author":"R Tussiwand","year":"2012","unstructured":"Tussiwand, R. et al. Compensatory dendritic cell development mediated by BATF\u2013IRF interactions. Nature 490, 502\u2013507 (2012).","journal-title":"Nature"},{"key":"3115_CR43","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-20-2564","volume":"27","author":"Y Liang","year":"2021","unstructured":"Liang, Y., Hannan, R. & Fu, Y.-X. Type I IFN activating type I dendritic cells for antitumor immunity. Clin. Cancer Res. 27, 3818\u20133824 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3115_CR44","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8\u03b1+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100 (2008).","journal-title":"Science"},{"key":"3115_CR45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","volume":"165","author":"Y Liu","year":"2016","unstructured":"Liu, Y., Beyer, A. & Aebersold, R. On the dependency of cellular protein levels on mRNA abundance. Cell 165, 535\u2013550 (2016).","journal-title":"Cell"},{"key":"3115_CR46","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.immuni.2020.05.005","volume":"52","author":"SL Nutt","year":"2020","unstructured":"Nutt, S. L. & Chopin, M. Transcriptional networks driving dendritic cell differentiation and function. Immunity 52, 942\u2013956 (2020).","journal-title":"Immunity"},{"key":"3115_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.immuni.2018.11.010","volume":"50","author":"M Chopin","year":"2019","unstructured":"Chopin, M. et al. Transcription factor PU.1 promotes conventional dendritic cell identity and function via induction of transcriptional regulator DC-SCRIPT. Immunity 50, 77\u201390.e5 (2019).","journal-title":"Immunity"},{"key":"3115_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00251-018-1082-2","volume":"71","author":"A Kelly","year":"2019","unstructured":"Kelly, A. & Trowsdale, J. Genetics of antigen processing and presentation. Immunogenetics 71, 161\u2013170 (2019).","journal-title":"Immunogenetics"},{"key":"3115_CR49","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.immuni.2006.08.009","volume":"25","author":"K Honda","year":"2006","unstructured":"Honda, K., Takaoka, A. & Taniguchi, T. Type I inteferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 25, 349\u2013360 (2006).","journal-title":"Immunity"},{"key":"3115_CR50","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-020-0731-4","volume":"21","author":"A Abbas","year":"2020","unstructured":"Abbas, A. et al. The activation trajectory of plasmacytoid dendritic cells in vivo during a viral infection. Nat. Immunol. 21, 983\u2013997 (2020).","journal-title":"Nat. Immunol."},{"key":"3115_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74\u201395 (2017).","journal-title":"Cell Res."},{"key":"3115_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13368-y","volume":"10","author":"CR Perez","year":"2019","unstructured":"Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 5408 (2019).","journal-title":"Nat. Commun."},{"key":"3115_CR53","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300\u20137306 (2015).","journal-title":"Nano Lett."},{"key":"3115_CR54","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","volume":"17","author":"MA Oberli","year":"2017","unstructured":"Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326\u20131335 (2017).","journal-title":"Nano Lett."},{"key":"3115_CR55","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.4049\/jimmunol.1101313","volume":"188","author":"DP Simmons","year":"2012","unstructured":"Simmons, D. P. et al. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 188, 3116\u20133126 (2012).","journal-title":"J. Immunol."},{"key":"3115_CR56","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan, Z. & Luo, Y. Targeting macrophages in cancer immunotherapy. Signal Transduct. Target. Ther. 6, 127 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3115_CR57","doi-asserted-by":"publisher","first-page":"G352","DOI":"10.1152\/ajpgi.00286.2005","volume":"290","author":"J Kim","year":"2006","unstructured":"Kim, J. et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G352\u2013G360 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"3115_CR58","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1182\/blood-2010-10-311456","volume":"117","author":"TA Waldmann","year":"2011","unstructured":"Waldmann, T. A. et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117, 4787\u20134795 (2011).","journal-title":"Blood"},{"key":"3115_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jir.2018.0019","volume":"39","author":"KC Conlon","year":"2018","unstructured":"Conlon, K. C., Miljkovic, M. D. & Waldmann, T. A. Cytokines in the treatment of cancer. J. Interferon Cytokine Res. 39, 6\u201321 (2018).","journal-title":"J. Interferon Cytokine Res."},{"key":"3115_CR60","doi-asserted-by":"publisher","first-page":"952231","DOI":"10.3389\/fimmu.2022.952231","volume":"13","author":"Z Jia","year":"2022","unstructured":"Jia, Z. et al. IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines. Front. Immunol. 13, 952231 (2022).","journal-title":"Front. Immunol."},{"key":"3115_CR61","first-page":"123","volume":"4","author":"D Xue","year":"2021","unstructured":"Xue, D., Hsu, E., Fu, Y.-X. & Peng, H. Next-generation cytokines for cancer immunotherapy. Antib. Ther. 4, 123\u2013133 (2021).","journal-title":"Antib. Ther."},{"key":"3115_CR62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/ijms24010123","volume":"24","author":"S Domingos-Pereira","year":"2023","unstructured":"Domingos-Pereira, S. et al. Tumor-microenvironment characterization of the MB49 non-muscle-invasive bladder-cancer orthotopic model towards new therapeutic strategies. Int. J. Mol. Sci. 24, 123 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"3115_CR63","doi-asserted-by":"publisher","first-page":"e004579","DOI":"10.1136\/jitc-2022-004579","volume":"10","author":"E Bruni","year":"2022","unstructured":"Bruni, E. et al. Intrahepatic CD69+V\u03b41 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. J. Immunother. Cancer 10, e004579 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"3115_CR64","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.it.2004.12.006","volume":"26","author":"D Sancho","year":"2005","unstructured":"Sancho, D., G\u00f3mez, M. & S\u00e1nchez-Madrid, F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 26, 136\u2013140 (2005).","journal-title":"Trends Immunol."},{"key":"3115_CR65","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1016\/j.cell.2022.10.006","volume":"185","author":"F Baharom","year":"2022","unstructured":"Baharom, F. et al. Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell 185, 4317\u20134332 (2022).","journal-title":"Cell"},{"key":"3115_CR66","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"3115_CR67","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1078-0432.CCR-13-2116","volume":"20","author":"A Marabelle","year":"2014","unstructured":"Marabelle, A., Kohrt, H., Caux, C. & Levy, R. Intratumoral immunization: a new paradigm for cancer therapy. Clin. Cancer Res. 20, 1747\u20131756 (2014).","journal-title":"Clin. Cancer Res."},{"key":"3115_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4049\/jimmunol.1601145","volume":"198","author":"MA Aznar","year":"2017","unstructured":"Aznar, M. A. et al. Intratumoral delivery of immunotherapy\u2014act locally, think globally. J. Immunol. 198, 31\u201339 (2017).","journal-title":"J. Immunol."},{"key":"3115_CR69","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/2326-6066.CIR-21-0865","volume":"10","author":"ST Ferris","year":"2022","unstructured":"Ferris, S. T. et al. cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. Cancer Immunol. Res. 10, 920\u2013931 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"3115_CR70","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"3115_CR71","doi-asserted-by":"publisher","first-page":"9815","DOI":"10.1021\/acsnano.8b00966","volume":"12","author":"K Van der Jeught","year":"2018","unstructured":"Van der Jeught, K. et al. Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety. ACS Nano 12, 9815\u20139829 (2018).","journal-title":"ACS Nano"},{"key":"3115_CR72","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/s41565-025-02044-6","volume":"20","author":"A Rudra","year":"2025","unstructured":"Rudra, A. et al. Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines. Nat. Nanotechnol. 20, 1831\u20131842 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"3115_CR73","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4049\/jimmunol.181.2.1215","volume":"181","author":"X Li","year":"2008","unstructured":"Li, X., Syrovets, T., Paskas, S., Laumonnier, Y. & Simmet, T. Mature dendritic cells express functional thrombin receptors triggering chemotaxis and CCL18\/pulmonary and activation-regulated chemokine induction. J. Immunol. 181, 1215\u20131223 (2008).","journal-title":"J. Immunol."},{"key":"3115_CR74","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1084\/jem.188.7.1359","volume":"188","author":"ML Albert","year":"1998","unstructured":"Albert, M. L. et al. Immature dendritic cells phagocytose apoptotic cells via \u03b1v\u03b25 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188, 1359\u20131368 (1998).","journal-title":"J. Exp. Med."},{"key":"3115_CR75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nnano.2010.250","volume":"6","author":"ZJ Deng","year":"2011","unstructured":"Deng, Z. J., Liang, M., Monteiro, M., Toth, I. & Minchin, R. F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotechnol. 6, 39\u201344 (2011).","journal-title":"Nat. Nanotechnol."},{"key":"3115_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100948","volume":"297","author":"C Cheng","year":"2021","unstructured":"Cheng, C. et al. Recognition of lipoproteins by scavenger receptor class A members. J. Biol. Chem. 297, 100948 (2021).","journal-title":"J. Biol. Chem."},{"key":"3115_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92711-0","volume":"11","author":"J Qu","year":"2021","unstructured":"Qu, J. et al. Low-density lipoprotein receptor-related protein 1 (LRP1) is a novel receptor for apolipoprotein A4 (APOA4) in adipose tissue. Sci. Rep. 11, 13289 (2021).","journal-title":"Sci. Rep."},{"key":"3115_CR78","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51, 8529\u20138533 (2012).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"3115_CR79","doi-asserted-by":"publisher","first-page":"113834","DOI":"10.1016\/j.addr.2021.113834","volume":"178","author":"A Gupta","year":"2021","unstructured":"Gupta, A., Andresen, J. L., Manan, R. S. & Langer, R. Nucleic acid delivery for therapeutic applications. Adv. Drug Deliv. Rev. 178, 113834 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3115_CR80","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","volume":"23","author":"C Li","year":"2022","unstructured":"Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543\u2013555 (2022).","journal-title":"Nat. Immunol."},{"key":"3115_CR81","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu, H., Lin, L., Zhang, Z., Zhang, H. & Hu, H. Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct. Target. Ther. 5, 209 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3115_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqae028","volume":"6","author":"N Vostrosablin","year":"2024","unstructured":"Vostrosablin, N. et al. mRNAid, an open-source platform for therapeutic mRNA design and optimization strategies. NAR Genom. Bioinform. 6, lqae028 (2024).","journal-title":"NAR Genom. Bioinform."},{"key":"3115_CR83","doi-asserted-by":"publisher","first-page":"2249816","DOI":"10.1002\/eji.202249816","volume":"53","author":"MB Lutz","year":"2023","unstructured":"Lutz, M. B. et al. Guidelines for mouse and human DC generation. Eur. J. Immunol. 53, 2249816 (2023).","journal-title":"Eur. J. Immunol."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03115-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03115-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03115-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:05:06Z","timestamp":1778663106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03115-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":83,"alternative-id":["3115"],"URL":"https:\/\/doi.org\/10.1038\/s41587-026-03115-2","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.G.A. has advised Alnylam, Sanofi, Translate Bio, oRNA Therapeutics and Combined Therapeutics. R.L. has advised Alnylam, Moderna and Combined Therapeutics. A list of entities with which R.L. is involved, compensated or uncompensated, is available online (\n                      \n                      ). Patent applications covering aspects of this work have been filed by D.G.A., A.G., K.R., R.D., R.W. and C.G. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}